LTA Kit ELISA

N° du produit ABIN577103

Détail du produit LTA Kit ELISA

Antigène: LTA (Lymphotoxin-alpha (LTA))

Reactivité: Humain

Méthode de détection: Colorimetric

Type de méthode: Sandwich ELISA

Application: ELISA

Fonction: This TNF- enzyme linked immunosorbent assay (ELISA) applies a technique called a quantitative sandwich immunoassay. The microtiter plate provided in this kit has been pre-coated with a monoclonal antibody specific to TNF- . Standards or samples are then added to the appropriate microtiter plate wells and incubated. After washing to remove unbound TNF- and other components of the sample, biotin-conjugated polyclonal antibody specific to TNF- is added and incubated. If present, TNF- will bind and become immobilized by the antibody pre-coated on the wells and then become

Analytical Method: Quantitative

Sensibilité: The minimum detectable quantities of human TNF- as observed by the standard curve generated for both Calibrator Diluent I and Calibrator Diluent II are 22.0 pg/mL and 11.0 pg/mL respectively. The two standard deviations above the mean optical density of the 16 replicates of the zero standard were defined as the minimum detectable quantities.

Ingrédients: Standards: 1 set/2 vials

Information d'application

Plaque: Pre-coated

Restrictions: For Research Use only

Stockage

Agent conservateur: Without preservative

Détail du antigène

Antigène: LTA (Lymphotoxin-alpha (LTA))

Autre désignation: Tumor Necrosis Factor beta (TNF-b) (LTA Produits)

Synonymes: LT Kit ELISA, TNFB Kit ELISA, TNFSF1 Kit ELISA, LT-[a] Kit ELISA, LT-alpha Kit ELISA, LT[a] Kit ELISA, LTalpha Kit ELISA, Ltx Kit ELISA, TNF-beta Kit ELISA, Tnfb Kit ELISA, Tnfsf1b Kit ELISA, hlb382 Kit ELISA, lymphotoxin alpha Kit ELISA, lymphotoxin A Kit ELISA, LTA Kit ELISA, Lta Kit ELISA

Classe de substances: Chemical

Sujet: Interleukin-6 (IL-6) is a multifunctional cytokine produced by a wide variety of cell types including monocyte/macrophages, T cells, fibroblasts, hepatocytes, vascular endothelial cells, cardiac myxomas, bladder cell carcinomas, myelomas, astrogliomas, and glioblastomas. The effects of IL-6 on different cell types are numerous and varied. These activities include: stimulation of B cell differentiation and antibody secretion; action as a co-stimulant with PHA or Con A to increase IL-2 production and IL-2 receptor expression by T cells; enhancement of differentiation of cytotoxic T cells; action as a growth factor for mature thymic or peripheral T cells, myelomas, hybridomas, plasmacytomas, keratinocytes, and mesangial cells; colony-stimulating activity on hematopoetic cells; induction of neuronal cell differentiation; induction of maturation of megakaryocytes; and stimulation of production of acute phase response proteins by hepatocytes. These various activities indicate that IL-6 plays a major role in the mediation of the inflammatory and immune responses initiated by infection or injury. Elevated IL-6 levels have been reported to be associated with a variety of diseases, including autoimmune diseases, mesangial proliferative glomerulonephritis, psoriasis, and malignancies such as plasmacytomas and myelomas. For reviews of the properties and activities of IL-6, see references 1 to 3. The biological activities of IL-6 are initiated by binding of the cytokine to a high affinity receptor complex consisting of two membrane glycoproteins; an 8 kDa component receptor that binds IL-6 with low affinity (IL-6R) and a signal-transducing component of 13 kDa (gp13) that does not bind IL-6 by itself, but is required for high affinity binding of IL-6 by the complex. IL-6R and gp13 have been cloned, sequenced and expressed (4-7). A soluble form of the IL-6 R with a molecular weight of approximately 5 kDa has been found in the urine of healthy adult humans (8), in culture medium conditioned by the growth of a human myeloma cell line (9), in culture supernatants from PHA-stimulated human PBMC and HTLV-1 positive T cell lines (1) and in the serum of HIV-seropositive blood donors (1). This soluble form of the receptor apparently arises from proteolytic cleavage of membrane-bound IL-6R. Soluble forms of human and mouse IL-6 have also been constructed by insertion of termination codons into the regions of the IL-6R cDNAs encoding the external portions of the receptors and prior to the transmembrane domains (11, 12). These soluble receptors have been expressed in COS7 and CHO cells (11, 12) and have been shown to bind IL-6 in solution and to augment the activity of IL-6 as a result of the binding of the IL-6/IL-6 sR complex to membrane-bound gp13 (11, 12). The S7.5(3) IL-6 sR 2 _x000C_ regulation in vivo of the shedding of the soluble IL-6Rs and the function and significance of these soluble receptors in biological fluids is not currently understood. It has been suggested, however, that pathogical states involving elevated levels to IL-6 might also be associated with increased production of soluble IL-6Rs (1). This IL-6sR ELISA is a 4.5-hour solid phase immunoassay readily applicable to measure IL-6sR levels in serum, plasma, cell culture supernatant, and other biological fluids in the range of to 2 pg/mL. It showed no cross reactivity with other cytokines tested. This IL-6sR ELISA is expected to be effectively used for further investigations into the relationship between IL-6sR and the various conditions mentioned

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process